Listed by the USPTO as OGUNBIYI, OLUWATOSIN A
Tech Center 1700 • Art Units: 1641 1645 1733
This examiner grants 64% of resolved cases
OGUNBIYI, OLUWATOSIN A has resolved 936 cases in Tech Center 1700 and Art Unit 1641. The allowance rate is 63.8%, the interview lift is 41.2%, and the median time to allowance is 1060 days. The interview lift is a substantial positive measure relative to the overall allowance rate, indicating that interview-focused prosecution may be especially relevant to outcome planning.
The principal companies are Denka Company Limited, University of Massachusetts, and THE GENERAL HOSPITAL Corporation. The leading firms are FOLEY & LARDNER LLP, MORRISON & FOERSTER LLP, and Barron & Young PLLC. The large resolved docket supports using this profile as a meaningful reference for Art Unit 1641, particularly when planning interviews and setting expectations for prosecution duration.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18705007 | A Subunit Cryptococcus Vaccine | Non-Final OA | University of Massachusetts |
| 17434349 | TREATMENT OF BENIGN NERVOUS SYSTEM TUMORS USING ATTENUATED SALMONELLA TYPHIMURIUM | Final Rejection | The General Hospital Corporation |
| 18826093 | INJECTABLE HYDROGEL FOR SUSTAINED CO-DELIVERY OF AN ANTIGEN AND AN ADJUVANT, AND USES THEREOF | Non-Final OA | The Regents of the University of California |
| 18418897 | LIPOTEICHOIC ACID FROM STAPHYLOCOCCUS EPIDERMIDIS AND ITS USE TO MODULATE NEURONAL ACTIVITY VIA PD-1 INHIBITORY SIGNALLING IN NEURONS | Non-Final OA | Northwestern University |
| 18693414 | IMMUNOCHROMATOGRAPHY DEVICE AND PRODUCTION METHOD THEREOF, AND METHOD FOR DETECTING TARGET BACTERIUM USING SAME | Final Rejection | ASAHI KASEI KABUSHIKI KAISHA |
| 18878828 | ANTI-PD-1 ANTIBODY FORMULATIONS | Non-Final OA | Amgen Inc. |
| 18293016 | MICROORGANISMS DISPLAYING VIRAL DECOY RECEPTORS | Non-Final OA | EVONIK OPERATIONS GMBH |
| 18344790 | SURFACE DISPLAYED FUSION PROTEINS | Non-Final OA | Clara Foods Co. |
| 18697325 | ENGINEERED VECTORS AND ORGANISMS CONTAINING THE SAME FOR ISOFLAVONE CONVERSION IN THE GUT | Non-Final OA | Board of Regents, The University of Texas System |
| 18863566 | IMMUNOBIOTICS FOR PREVENTING BACTERIAL PNEUMONIA AND METHODS OF USING THE SAME | Non-Final OA | The Regents of the University of Colorado, A Body Corporate |
| 18739401 | POLYNUCLEOTIDE COMPOSITIONS AND USES THEREOF | Non-Final OA | Pfizer Inc. |
| 18741976 | LYME DISEASE RNA VACCINE | Non-Final OA | SANOFI PASTEUR INC. |
| 18833175 | METHOD FOR DETECTING HELICOBACTER SUIS ANTIBODY USING WHOLE CELL | Non-Final OA | DENKA COMPANY LIMITED |
| 17426557 | IMMUNOCHROMATOGRAPHIC TEST STRIP FOR EXTRACTING AND MEASURING SUGAR CHAIN ANTIGENS, CAPABLE OF CONTROLLING THE DEVELOPMENT OF SPECIMEN BY IMPREGNATING HYDROPHILIC MATERIAL WITH NITRITE OR SOLID ACID REAGENT | Non-Final OA | Denka Company Limited |
| 18705636 | ENHANCER OF NUMBER OF TCR CLONES | Non-Final OA | KABUSHIKI KAISHA YAKULT HONSHA |
| 18549804 | COMPOSITION AND AMELIORATING AGENT HAVING INFLAMMATION REDUCING EFFECT | Non-Final OA | KYOWA HAKKO BIO CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy63.8% of resolved applications examined by Oluwatosin A Ogunbiyi were allowed (936 resolved cases), compared with 45.2% across Art Unit 1641 over the last five years.
This examiner's interview lift is +41.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Oluwatosin A Ogunbiyi took 1,060 days on average from filing to allowance.
Oluwatosin A Ogunbiyi examines applications in Art Unit 1641 in Tech Center 1700 (Chemistry & Materials).
